Last $3.02 USD
Change Today +0.11 / 3.78%
Volume 1.6M
CTIX On Other Exchanges
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

cellceutix corp (CTIX) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/30/14 - $3.03
52 Week Low
12/4/13 - $1.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLCEUTIX CORP (CTIX)

Related News

No related news articles were found.

cellceutix corp (CTIX) Related Businessweek News

No Related Businessweek News Found

cellceutix corp (CTIX) Details

Cellceutix Corporation, a clinical stage biopharmaceutical company, focuses on discovering and developing small molecule drugs to treat drug-resistant cancers, psoriasis, autism, and inflammatory diseases. Its flagship compounds include Kevetrin, an anti-cancer compound that is in Phase I clinical trial for the treatment of cancer; Prurisol, an anti-psoriasis drug candidate that has completed Phase I clinical trial; and Brilacidin, an antibiotic candidate for the treatment of diabetic foot ulcer infections, and other indications, such as ophthalmic and otitic infections, as well as for other skin infections and oral mucositis. The company’s preclinical stage compounds comprise KM 391 for the treatment of autism; KM 277 for the treatment of rheumatoid arthritis; KM 278 for the treatment of arthritis/asthma; KM 362 for the treatment of MS/ALS/Parkinson’s disease; KM-3174 for the treatment of cancer; and KM-732 for hypertensive emergency, as well as Delparantag, a synthetic small-molecule for the treatment of other diseases, including chronic obstructive pulmonary disease. In addition, its other product candidates include compounds active against other gram-negative bacterias, malaria, tuberculosis, biowarfare pathogens, and PolyCide antimicrobial biomaterials. The company was founded in 2007 and is headquartered in Beverly, Massachusetts.

9 Employees
Last Reported Date: 09/15/14
Founded in 2007

cellceutix corp (CTIX) Top Compensated Officers

Chairman, Chief Executive & Financial Officer...
Total Annual Compensation: $444.7K
President, Chief Scientific Officer and Direc...
Total Annual Compensation: $444.7K
Compensation as of Fiscal Year 2014.

cellceutix corp (CTIX) Key Developments

Cellceutix Corporation Announces Update on its Recently Completed Phase 2B Study of Brilacidin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Cellceutix Corporation announced this update on its recently completed Phase 2b study of Brilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infections ('ABSSSI'). The study was a 215-patient blinded trial with four treatment arms and approximately 50-55 patients per arm. Three of the arms evaluated Brilacidin, two single-dose arms and one 3-day regimen, and the fourth arm was daptomycin of once per day for seven days. Daptomycin for injection is marketed by Cubist Pharmaceuticals under the brand name Cubicin(R) and generated approximately $447 million in sales in the first half of 2014. The initial results from the study are general observations and only considered blinded data averaged across all four treatment groups. Similar to a previously conducted Phase 2a study, Staphylococcus aureus (including MRSA) was the most common bacteria isolated at the baseline visit. The data shows that by Day 7, the average cure rate for all four treatment arms was higher than what was observed in the phase 2a study, and similar to - if not higher than - cure rates reported for common ABSSSI drugs, as well as those approved this year. Because 3/4 of the patients in this study were treated with Brilacidin, this high average cure rate is heavily influenced by Brilacidin, and less influenced by daptomycin, which only 1/4 patients received. This also means that the two single-dose treatment arms are providing half of the data toward this positive average cure rate; and if these data hold up, a single-dose regimen of Brilacidin would be the Company's Phase 3 study design. Oral mucositis is a common and often debilitating inflammation and ulceration in the mouth as a side effect of certain cancer treatments, including chemotherapy and radiation therapy that affects nearly half a million people each year. Laboratory studies of Brilacidin-OM have demonstrated antibacterial, anti-biofilm and anti-inflammatory properties of Brilacidin-OM as an oral rinse that significantly reduced the duration of oral mucositis by 90% or more. There are currently no FDA-approved preventative or therapeutic drugs to treat oral mucositis induced by a broad spectrum of cancer therapies.

Cellceutix Corporation Appoints Barry Schechter as A Board of Director Effective October 1, 2014

On September 2, 2014, the Board of Directors of Cellceutix Corporation appointed Dr. Barry Schechter to the company's Board of Directors, effective October 1, 2014. Dr. Barry Schechter, M.D., F.A.A.O., is the Director of Department of Cornea and External Disease at Florida Eye Microsurgical Institute. Dr. Schechter is involved in clinical research and consults for several ophthalmic pharmaceutical companies. Dr. Schechter brings years of experience to the company through his specialization in ocular pathology and diseases, including infections.

Cellceutix Corporation Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Cellceutix Corporation announced the completion of enrollment in its Phase 2b trial comparing Brilacidin(TM) to daptomycin (Cubicin(R)) in patients with acute bacterial skin and skin structure infections (ABSSSI). Overall, 215 patients were randomized to one of three dosing regimens of Brilacidin (single dose 0.6mg/kg; single-dose 0.8mg/kg; 1.2mg/kg over 3 days) or 7 days of once daily daptomycin. Brilacidin is the lead compound among a novel class of antibiotics known as defensin-mimetics. These compounds have shown great promise in preclinical and early clinical studies as potent antibiotics that can kill Staph aureus, including methicillin-resistant Staph aureus (MRSA). Moreover, given the unique mechanism of action, among other attributes, there is low, if any, potential for the development of resistance. Finally, the results of the current study may demonstrate that Brilacidin could be given as a single-dose, which provides benefits for both patients and society. This combination of properties makes Brilacidin unique among antibiotics recently approved or in development for the treatment of MRSA. Because these other compounds come from existing classes of antibiotics, there is the potential for cross-resistance; this is not the case for Brilacidin.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTIX:US $3.02 USD +0.11

CTIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CTIX.
View Industry Companies

Industry Analysis


Industry Average

Valuation CTIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 244.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLCEUTIX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at